Abcuro
Clinical-stage immunotherapies targeting pathogenic cytotoxic T cells in autoimmune disease.
$66MSeries D
Role not disclosedSB
Samsara BioCapital
Activity from announced rounds
Activity in this selectionnomura-real-estate-development-co-f095adde
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 4 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $715M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionSidewinder Therapeutics
Develops next-generation bispecific ADCs for cancer treatment
$137MSeries B
Role not disclosedAmbrosia Biosciences
Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.
$100MSeries B
ParticipantEpiBiologics
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...
$107MSeries B
Role not disclosedParabilis Medicines
Develops medicines targeting historically undruggable protein targets in cancer
$305MSeries F
Role not disclosed